Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan rollover study in advanced solid tumors and VHL-related tumors
NL-OMON61088Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of belzutifan in renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), colorectal cancer (CRC) and 10 more, sponsored by Merck & Co. Primary endpoint: Overall survival. Started May 2026; status: recruiting.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)biliary cancer
Beyond the preview
Go deeper on NL-OMON61088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61088.